Literature DB >> 24799844

Commentary: vedolizumab: a new mechanism of action for the treatment of ulcerative colitis.

Stefan Schreiber1.   

Abstract

Entities:  

Year:  2014        PMID： 24799844      PMCID： PMC4008964     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  7 in total

Review 1.  Molecular basis of leukocyte-endothelium interactions during the inflammatory response.

Authors:  Olga Barreiro; Francisco Sánchez-Madrid
Journal:  Rev Esp Cardiol       Date:  2009-05       Impact factor: 4.753

2.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

Review 3.  Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.

Authors:  Alexander C Ford; William J Sandborn; Khurram J Khan; Stephen B Hanauer; Nicholas J Talley; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2011-03-15       Impact factor: 10.864

4.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-14       Impact factor: 22.682

5.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

6.  The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.

Authors:  Dulce Soler; Tobias Chapman; Li-Li Yang; Tim Wyant; Robert Egan; Eric R Fedyk
Journal:  J Pharmacol Exp Ther       Date:  2009-06-09       Impact factor: 4.030

7.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Toshifumi Hibi; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-02       Impact factor: 22.682
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.